18F-fluorodeoxyglucose-positron emission tomography before, during and after treatment in mature T/NK lymphomas: a study from the GOELAMS group.
BACKGROUND
In non-cutaneous T-cell/natural killer (T/NK) lymphomas, the prognostic value of (18)F-fluorodeoxyglucose-positron emission tomography (FDG-PET) during or after therapy is unknown.


METHODS
In this retrospective study, 54 T/NK lymphoma patients were assessed using FDG-PET before (n = 40), during (n = 44) and/or after therapy (n = 31).


RESULTS
FDG-PET showed an abnormal FDG uptake in all cases. Interim FDG-PET was negative in 25 of 44 cases. After completion of therapy, 19 of 31 patients reached complete remission with negative FDG-PET. In ALK+ anaplastic large cell lymphomas, the 4-year progression-free survival (PFS) was 80% and the negative predictive value of post-therapy FDG-PET was 83% (n = 9). In ALK- T/NK lymphomas, the 4-year PFS was 59% for patients with a negative interim FDG-PET versus 46% for patients with a positive interim FDG-PET (P = 0.28, n = 35). Similarly, there was no statistical difference in 4-year PFS between negative and positive post-therapy FDG-PET in these lymphomas (51% and 67%, respectively, P = 0.96). The 4-year cumulative incidence of relapse from a negative post-therapy FDG-PET was 53% in ALK- T/NK lymphomas.


CONCLUSIONS
Although T/NK lymphomas are FDG-avid at diagnosis, a negative interim or post-therapy FDG-PET does not translate into an improved PFS in ALK- T/NK lymphomas.
Cahu
X
X
Department of Hematology.
Bodet-Milin
C
C
Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes.
Brissot
E
E
Department of Hematology.
Maisonneuve
H
H
Department of Hematology, Centre Hospitalier Départemental La Roche-sur-Yon.
Houot
R
R
Department of Hematology, Hôpital Pontchaillou, Centre Hospitalier Universitaire Rennes, Rennes.
Morineau
N
N
Department of Hematology, Centre Catherine de Sienne, Nantes.
Solal-Celigny
P
P
Department of Hematology and Oncology, Centre Jean Bernard, Clinique Victor Hugo, Le Mans.
Godmer
P
P
Department of Hematology, Centre Hospitalier Départemental Vannes, Vannes.
Gastinne
T
T
Department of Hematology.
Moreau
P
P
Department of Hematology.
Moreau
A
A
Department of Pathology, Centre Hospitalier Universitaire Nantes, Nantes.
Lamy
T
T
Department of Hematology, Hôpital Pontchaillou, Centre Hospitalier Universitaire Rennes, Rennes; Research Unit, Inserm U917, Université de Rennes I, Rennes.
Kraber-Bodere
F
F
Department of Nuclear Medicine, Centre Hospitalier Universitaire Nantes; Center for Oncology Research Nantes/Angers, Inserm UMR 892, Nantes; Department of Nuclear Medicine, Centre René Gauducheau, Saint-Herblain.
Le Gouill
S
S
Department of Hematology; Center for Oncology Research Nantes/Angers, Inserm UMR 892, Nantes; Center for Clinical Investigation in Oncology (CI2C), Centre Hospitalier Universitaire Nantes, France. Electronic address: steven.legouill@chu-nantes.fr.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D018572:Disease-Free Survival; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D053208:Kaplan-Meier Estimate; D054391:Lymphoma, Extranodal NK-T-Cell / Q000000981:diagnostic imaging / Q000401:mortality / Q000628:therapy; D016399:Lymphoma, T-Cell / Q000000981:diagnostic imaging* / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D055815:Young Adult
D000970:Antineoplastic Agents; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18